Positions

Overview

  • Steven M. Rowe was born in Baton Rouge, LA in May 1972. He received his BA degree from the University of Virginia in 1994, his medical degree from Vanderbilt University in 1998, and an MSPH from the University of Alabama at Birmingham in 2005. He completed a combined Internal Medicine and Pediatrics internship and residency at the University of Alabama at Birmingham. He also completed a combined Pulmonary and Critical Care Medicine and Pediatric Pulmonary fellowship at the University of Alabama at Birmingham.
    In 2014, Dr. Rowe was promoted to Professor with tenure in the Departments of Medicine (Pulmonary, Allergy, and Critical Care Medicine), Pediatrics (Pediatric Pulmonology), and Cell Developmental and Integrative Biology. He is the Director of the Gregory Fleming Cystic Fibrosis Research Center, which involves over 100 faculty members and has been continuously funded for over 25 years. Dr. Rowe is board certified in Internal Medicine, Pediatrics, Pulmonary Medicine and Critical Care Medicine and serves as a Special Consultant for Translational Science for the Cystic Fibrosis Foundation.
    Dr. Rowe has a remarkable ability to identify, establish, and cultivate effective collaborations across institutional and geographic boundaries. He established a prolific six-year collaboration with Dr. Guillermo Tearney to advance µOCT imaging for use in respiratory epithelia to ask seminal questions in airway biology. Dr. Rowe initiated an eight-year collaboration with Dr. Mark Dransfield to investigate acquired CFTR dysfunction in COPD. He has a seven-year collaboration with Dr. David Bedwell to advance translational readthrough approaches for genetic disease. Dr. Rowe is also highly effective in research consortia. He leads the International Mucus Clearance Consortium, involving Fundamental and translational scientists. He is also a key member of the cystic fibrosis research community, helping lead the Cystic Fibrosis Therapeutics Development Network through the Center for CFTR Detection.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 A phase 3 open-label study of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del alleleAmerican Journal of Respiratory and Critical Care Medicine.  203:1522-1532. 2021
    2020 Ivacaftor reverses airway mucus abnormalities in a rat model harboring a humanized G551D-CFTRAmerican Journal of Respiratory and Critical Care Medicine.  202:1271-1282. 2020
    2020 Novel therapy of bicarbonate, glutathione, and ascorbic acid improves cystic fibrosis mucus transportAmerican Journal of Respiratory Cell and Molecular Biology.  63:362-373. 2020
    2020 Airway remodeling in ferrets with cigarette smoke-induced COPD using μCT imaging 2020
    2019 Vaporized e-cigarette liquids induce ion transport dysfunction in airway epitheliaAmerican Journal of Respiratory Cell and Molecular Biology.  61:162-173. 2019
    2018 Functional anatomic imaging of the airway surfaceAnnals of the American Thoracic Society.  15:S177-S183. 2018
    2018 Maternal smoking induces acquired CFTR dysfunction in neonatal ratsAmerican Journal of Respiratory and Critical Care Medicine.  198:672-674. 2018
    2018 Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvementAmerican Journal of Respiratory and Critical Care Medicine.  197:1483-1486. 2018
    2018 MicroRNA-145 antagonism reverses TGF-b inhibition of F508del CFTR correction in airway EpitheliaAmerican Journal of Respiratory and Critical Care Medicine.  197:632-643. 2018
    2016 Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutationsAmerican Journal of Respiratory and Critical Care Medicine.  194:1092-1103. 2016
    2015 Recovery of acquired cystic fibrosis transmembrane conductance regulator dysfunction after smoking cessationAmerican Journal of Respiratory and Critical Care Medicine.  192:1521-1524. 2015
    2015 Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated mice 2015
    2014 An autoregulatory mechanism governing mucociliary transport is sensitive to mucus loadAmerican Journal of Respiratory Cell and Molecular Biology.  51:485-493. 2014
    2014 A functional anatomic defect of the cystic fibrosis airwayAmerican Journal of Respiratory and Critical Care Medicine.  190:421-432. 2014
    2014 Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosisAmerican Journal of Respiratory and Critical Care Medicine.  190:175-184. 2014
    2014 Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitisAmerican Journal of Respiratory Cell and Molecular Biology.  50:549-558. 2014
    2013 Cigarette smoke and CFTR: Implications in the pathogenesis of COPD 2013
    2013 Cystic fibrosis chronic rhinosinusitis: A comprehensive review 2013
    2011 Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators 2011
    2011 Quercetin increases cystic fibrosis transmembrane conductance regulator-mediated chloride transport and ciliary beat frequency: Therapeutic implications for chronic rhinosinusitis 2011
    2010 Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: Potential use as a biomarker of ΔF508 cystic fibrosis transmembrane conductance regulator rescueAmerican Journal of Respiratory Cell and Molecular Biology.  43:607-616. 2010
    2007 Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trialsAnnals of the American Thoracic Society.  4:387-398. 2007
    2007 No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutationsAmerican Journal of Respiratory Cell and Molecular Biology.  37:57-66. 2007

    Research Overview

  • Dr. Rowe specializes in developing new treatments for cystic fibrosis, the most common autosomal recessive genetic disease, and the cause of severe pulmonary disease affecting children and young adults. He founded the CF Transition Clinic for adolescents and young adults with the disease. He maintains expertise in the design and conduct of clinical trials targeting the basic CF defect. Dr. Rowe also has an interest in biomarkers of CF and other related airway diseases including measures of ion transport and the relation between mucus stasis and inflammation. He currently directs a clinical research program that examines the relationship between CF and the chronic bronchitis of COPD.

    Dr. Rowe is an accomplished academic physician scientist- a pioneer in the field of personalized therapeutics for CF, cutting-edge discovery in airway disease biology, and translational research. He is a respected authority in the design and conduct of clinical trials targeting the basic CF defect and has made key advances in the measurement and interpretation of CFTR function in humans and animals. In a related effort, Dr. Rowe has advanced both the molecular and clinical understanding of suppression of premature termination codons, representing an exciting strategy for treatment of genetic diseases caused by nonsense mutations, which are responsible for approximately 10 percent of all genetic diseases.
    Dr. Rowe has recently discovered that COPD patients exhibit acquired CFTR dysfunction through a pathway that causes delayed mucociliary clearance and confers chronic bronchitis. The approach establishes how a single gene in a rare disorder can contribute to the third leading cause of death and has lead to new efforts to evaluate CFTR modulators in patients with chronic bronchitis, potentially leading to a new paradigm for COPD treatment. Dr. Rowe co-invented one-micron resolution optical coherence tomography that captures 3D imaging in real time at the cellular level. The technique is highly sensitive to the epithelial function of airway tissues and can provide simultaneous and non-invasive measurements of the functional microanatomy of the airway surface, significantly advancing our understanding of airway disease pathogenesis.
  • Principal Investigator On

  • A Pilot Study of the Effect of the CFTR Potentiator Ivacaftor in COPD (P-Topic)  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Study)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Study) (PROMISE-OB-18)  awarded by Cystic Fibrosis Foundation ^
  • A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT)  awarded by Cystic Fibrosis Foundation ^
  • A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT) ("Clinical Study")  awarded by SEATTLE CHILDREN'S HOSPITAL
  • An Open Label N of 1 Study to Evaluate the Safety and Efficacy of Long-Term Treatment with Ivacaftor in Combination with ALTALUREN (PTCD124) In Subjects with Nonsense Mutation Cystic Fibrosis  awarded by University of Pennsylvania
  • Assessing Response of B-Adrenergic Sweat Secretion in Patients with R117H Mutations Following Treatment with Ivacaftor (GOALe2 Ancillary)  awarded by Cystic Fibrosis Foundation ^
  • Bacterial-host Interactions in Cystic Fibrosis Chronic Respiratory Infections  awarded by Cystic Fibrosis Foundation ^
  • Brevenal Effect on Mucociliary Clearance for Treatment of CF Mucus  awarded by Cystic Fibrosis Foundation ^
  • CFF Clinical Fellowship  awarded by Cystic Fibrosis Foundation ^
  • CFTR Functional Restoration by Antisense Oligonucleotides  awarded by Cystic Fibrosis Foundation ^
  • Characterization of Novel Translational Readthrough Agents Discovered by High Throughput Screening  awarded by Cystic Fibrosis Foundation ^
  • Characterizing CFTR Modulated Changes in Sweat Chloride & Clinical Outcomes  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • Characterizing CFTR Modulated Changes in Sweat Chloride and Clinical Outcomes  awarded by UNIVERSITY OF COLORADO DENVER - NEW
  • Clinical and Mechanistic Features of Premature Termination Codon Suppression  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Consultant for Translational Science  awarded by Cystic Fibrosis Foundation ^
  • Consultant for Translational Science  awarded by Cystic Fibrosis Foundation ^
  • Core Center for Measurements of Mucus and Mucociliary Clearance  awarded by Cystic Fibrosis Foundation ^
  • Core Center for Measurements of Mucus and Mucociliary Clearance  awarded by Cystic Fibrosis Foundation ^
  • Cystic Fibrosis Fibrosing Colonopathy Observational (CFFC-OB-11)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • Development of High Through-Put Screening by SD-OCT in Primary Human Bronchial Epithelial Cells  awarded by FLATLEY DISCOVERY LAB, LLC
  • Development of Optical Coherence Tomography for Measures of Mucociliary Clearance  awarded by MASSACHUSETTS GENERAL HOSPITAL
  • Development of Optical Coherence Tomography for Measures of Mucociliary Clearance (MCC)  awarded by MASSACHUSETTS GENERAL HOSPITAL
  • Effect of PAAG Treatment on CF Related Pseudomonas Infected Respiratory Epithelium  awarded by Cystic Fibrosis Foundation ^
  • Evaluation of Approved Drug Libraries for Translational Readthrough Activity  awarded by Cystic Fibrosis Foundation ^
  • Evaluation of Arina-1 for the Treatment of Cystic Fibrosis Lung Disease  awarded by CYSTIC FIBROSIS FOUNDATION THERAPEUTICS., INC
  • Functional Anatomic Imaging of CF Patients with Early Lung Disease Using microOCT  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • G551D Observational Study (GOAL-OB-11)  awarded by Cystic Fibrosis Foundation ^
  • G551D Observational Study-Expanded to Additional Genotypes and Extended for Long Term Follow-Up (GOAL-e2)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • G551D Observational Study-SEATTLE GOAL  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • Genetic Modifiers of Cystic Fibrosis  awarded by Johns Hopkins University
  • Idiopathic Pulmonary Fibrosis, A Disease Initiated by Mucociliary Dysfunction  awarded by UNIVERSITY OF COLORADO DENVER - NEW
  • Individual Project Schedule #6.0  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • Mechanism of Aberrant Mucus Adhesion and Stasis in the CF Airways  awarded by Cystic Fibrosis Foundation ^
  • Mechanisms of and Therapies for Abnormal Mucus Adhesion and Clearance in CF  awarded by Cystic Fibrosis Foundation ^
  • Mechanistic Basis Underlying Protein Repair of CFTR Nonsense Mutations  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Mechanistic Link Between Rescue of CFTR Mediated Anion Transport, Airway Surface Liquid Regulation, and Mucociliary Transport by CFTR Modulators  awarded by Cystic Fibrosis Foundation ^
  • Micro-CT Scanner for Ultra-High Resolution Live Imaging of Large and Small Animals  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • Molecular Pathogenesis and Phenotype of Acquired CFTR Dysfunction in COPD  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Molecular Pathogenesis and Phenotype of Acquired CFTR Dysfunction in COPD  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Mucociliary Clearance National Resource Center  awarded by University of North Carolina at Chapel Hill
  • Mucus Matters: Mucociliary Physiology in Pulmonary Fibrosis  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Nasal Epithelial Cells as an Outcome Tool for Individualized CFTR Therapies  awarded by Cystic Fibrosis Foundation ^
  • Private Grant  awarded by PTC THERAPEUTICS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by PTC THERAPEUTICS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by HEMAQUEST PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by SYNEDGEN, INC
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by SYNEDGEN, INC
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW
  • Private Grant  awarded by DISCOVERY BIOMED, LLC ^
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by Bayer AG
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
  • Private Grant  awarded by GALAPAGOS NV.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by PTC THERAPEUTICS, INC.
  • Private Grant  awarded by PTC THERAPEUTICS, INC.
  • Private Grant  awarded by Bayer HealthCare
  • Private Grant  awarded by Bayer AG
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by SYNEDGEN, INC
  • Private Grant  awarded by PROGENRA, INC.
  • Private Grant  awarded by ELOXX PHARMACEUTICALS
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by RAPTOR PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by GALAPAGOS NV.
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by ORPRO THERAPEUTICS
  • Private Grant  awarded by PROQR THERAPEUTICS
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC.
  • Private Grant  awarded by PTC THERAPEUTICS, INC.
  • Private Grant  awarded by CFD RESEARCH CORPORATION
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by TRANSLATE BIO, INC ^
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by PTC THERAPEUTICS, INC.
  • Private Grant  awarded by GALAPAGOS NV.
  • Private Grant  awarded by SYNEDGEN, INC
  • Private Grant  awarded by PULMOTECT
  • Private Grant  awarded by ELOXX PHARMACEUTICALS
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC.
  • Private Grant  awarded by TRANSLATE BIO, INC ^
  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC.
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC.
  • Private Grant  awarded by TRANSLATE BIO, INC ^
  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC.
  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC.
  • Private Grant  awarded by ELEVEN P15 INC
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC.
  • Private Grant  awarded by ELOXX PHARMACEUTICALS
  • Private Grant  awarded by TRANSLATE BIO, INC ^
  • Research Development Program  awarded by Cystic Fibrosis Foundation ^
  • Restoration of the CFTR Function by Splicing Modulation  awarded by Cystic Fibrosis Foundation ^
  • Systemic CFTR Dysfunction Induced by Acrolein in Cigarette Smoke: A Novel Therapeutic Target for COPD  awarded by American Lung Association
  • TDN Additional Research Coordinator (ARC)  awarded by Cystic Fibrosis Foundation ^
  • The 2015 TDN Spring Meeting  awarded by Cystic Fibrosis Foundation ^
  • The De-Novo Generation of Pulmonary Ionocytes from Human Pluripotent Stem Cells  awarded by Boston University
  • The Identification of New Treatments for Cystic Fibrosis Caused by Premature Termination Codons  awarded by SOUTHERN RESEARCH INSTITUTE
  • The Mechanism of Tobacco-Induced Decrements in Mucociliary Clearance  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • The Mucociliary Clearance Defect of the Cystic Fibrosis Rat  awarded by Cystic Fibrosis Foundation ^
  • Therapeutic Development Center - UAB Center for CFTR Detection  awarded by Cystic Fibrosis Foundation ^
  • Therapeutic Targeting of MUC5B in a Novel Ferret Model of Idiopathic Pulmonary Fibrosis  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Training and Equipment for the MBW sub-study of the PROSPECT Study.  awarded by Cystic Fibrosis Foundation ^
  • Translational Program in CFTR-Related Airway Diseases  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation ^
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - Admin Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - Admin Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - Core C  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - Core C  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - Core C - Clinical Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - Core C: Clinical & Translational Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - Engineered PF Phage to treat pseudomonas aeruginosa biofilm infections  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - P&F Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - Pilot Project 1 - Mucoid Steptococcus Pseumoniae in the CF Lung  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - Pilot and Feasibility  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Center for CFTR Detection  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Translational Development Center  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation ^
  • UAB Research and Development Program  awarded by Cystic Fibrosis Foundation ^
  • UAB Therapeutic Development Network Center  awarded by Cystic Fibrosis Foundation ^
  • UAB U-SPECT6CTUHROI Imager  awarded by NIH - OFFICE OF THE DIRECTOR
  • Using Chamber Studies to Characterize CFTR Modulators  awarded by Cystic Fibrosis Foundation ^
  • Investigator On

  • A Master Protocol to Test the Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • CFF Yr 3-Reproductive and Sexual Health Care in Young Women with CFF  awarded by University of Pittsburgh The
  • Center for Clinical and Translational Science (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS
  • Dysbiosis of the Sinus Microbiota in Chronic Rhinosinusitis  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Dysbiosis of the Sinus Microbiota in Chronic Rhinosinusitis  awarded by Cystic Fibrosis Foundation ^
  • Exacerbation of Influenza Secondary Infections in Cystic Fibrosis  awarded by Cystic Fibrosis Foundation ^
  • Losartan as Anti-Inflammatory Therapy to Augment F508del CFTR Recovery  awarded by University of Miami
  • Mechanisms of and Therapies for Abnormal Mucus Adhesion and Clearance in CF  awarded by Cystic Fibrosis Foundation ^
  • MiR-145 Mediated TGF-Beta Pathobiology in CF  awarded by Cystic Fibrosis Foundation ^
  • Novel Therapeutic Approaches for Treatment of CF Patients with W1282X Premature Termination Codon Mutations  awarded by EMILY'S ENTOURAGE
  • Oligotherapeutics to Enhance CFTR Correction  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Overcoming Barriers to F508del CFTR Correction  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Pediatric Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation ^
  • Pharmacometric Approaches to Precision Optimization of Ivacaftor Response in Cystic Fibrosis Patients  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients with Cystic Fibrosis  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • Private Grant  awarded by FOREST LABORATORIES, INC.
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by PROQR THERAPEUTICS
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by CELTAXSYS, INC.
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW
  • Private Grant  awarded by PARION SCIENCES, INC.
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by ELECTROMED, INC.
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC.
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC.
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC.
  • Private Grant  awarded by ELOXX PHARMACEUTICALS
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Proof of Principal Evaluation of IV Gallium Nitrate (Ganite) in Patients with Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL
  • Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL
  • Rare CFTR Mutation Cell Collection Protocol (RARE)  awarded by SEATTLE CHILDREN'S HOSPITAL
  • Standardized Treatment of Pulmonary Exacerbations II  awarded by SEATTLE CHILDREN'S HOSPITAL
  • Sweat Gland Culture Techniques for the Study of Cystic Fibrosis  awarded by Cystic Fibrosis Foundation ^
  • Tuning Aminoglycosides for Treatment of Genetic Diseases  awarded by Technion Israel Institute of Technology
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB CF Research and Translation Core Center - A Multicenter Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The Multicenter Topic Trial).  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS
  • UAB Center for Clinical and Translational Science (CCTS) (3 linked awards: UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS
  • UAB Center for Clinical and Translational Science (CCTS) UL1  awarded by National Center for Advancing Translational Sciences/NIH/DHHS
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research (Adult)  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Therapeutic Development Network Center for CFTR Detection  awarded by Cystic Fibrosis Foundation ^
  • UAB Research Development Program Component II - Overall Program  awarded by Cystic Fibrosis Foundation ^
  • miR-145 Target Site Blockade is a Selective Strategy to Enhance CFTR Restoration and Readthrough  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • miR-145 Target Site Blockade to Amplify CFTR Correction  awarded by Cystic Fibrosis Foundation ^
  • Education And Training

  • UAB Hospital, Internship
  • UAB Hospital, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Master of Science in Biostatistics, University of Alabama at Birmingham 2005
  • Doctor of Medicine, Vanderbilt University 1998
  • Full Name

  • Steven Rowe